EyePoint stock crashed Monday after its eye disease treatment, Duravyu, missed the mark in a final-phase study. The post The Surprising Reason EyePoint Just Crashed 69% appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real